Glucagon-like peptide-1 (GLP-1) drugs such as semaglutide and tirzepatide have revolutionized obesity care. The growing use of these drugs raises concerns about side effects. There are questions about the long-term results of treatment. Unregulated products are also a problem. Ensuring safe access requires supervision and monitoring. Coordinated clinical care is essential. Authors Ariana M. Chao, Adam Gilden, and Thomas A. Wadden discuss these aspects in perspective.